News Releases

Summary ToggleData reported at HepDart 2015 demonstrates reduced cytotoxicity compared to TDF and low potential for mitochondrial toxicity EDISON, N.J. , Dec. 8, 2015 / PRNewswire / -- ContraVir Pharmaceuticals, Inc. (NASDAQ:  CTRV ), a biopharmaceutical company focused on the development and

Summary ToggleEDISON, N.J. , Dec. 3, 2015 / PRNewswire / -- ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today Arnold Lippa , Ph.D., has joined the Company's Board of Directors. 

Summary ToggleData to Highlight CMX157's Significant Potential Compared to Viread® for Treating Hepatitis B EDISON, N.J. , Dec. 1, 2015 / PRNewswire / -- ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral

Summary ToggleEDISON, N.J. , Nov. 10, 2015 / PRNewswire / -- ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that it will present at the Salomon Bio Investment & Leadership

Summary ToggleEDISON, N.J. , Oct. 14, 2015 / PRNewswire / -- ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that it will present at at The 14th Annual BIO Investor Forum to be held

Summary ToggleEDISON, N.J. , Oct. 13, 2015 / PRNewswire / -- ContraVir Pharmaceuticals, Inc. (Nasdaq: CTRV) ("ContraVir" or the "Company"), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, today announced the closing of its previously announced

Summary ToggleEDISON, N.J. , Oct. 7, 2015 / PRNewswire / -- ContraVir Pharmaceuticals, Inc. (Nasdaq: CTRV) ("ContraVir" or the "Company"), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, today announced the pricing of an underwritten public

Summary ToggleEDISON, N.J. , Oct. 6, 2015 / PRNewswire / --   ContraVir Pharmaceuticals, Inc. (Nasdaq: CTRV) ("ContraVir" or the "Company"), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, today announced that it intends to offer shares of its

Summary ToggleEDISON, N.J. , Oct. 5, 2015 / PRNewswire / -- ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, today announced preliminary data dramatizing  the unique properties of CMX157, the

Summary ToggleEDISON, N.J. , Sept. 1, 2015 / PRNewswire / -- ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that it will present at the Rodman & Renshaw 17 th Annual Global